Jazz Pharmaceuticals Balances Record Gains With Slower 2026
Jazz Pharmaceuticals ((JAZZ)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jazz Pharmaceuticals’ latest earnings call struck an upbeat tone, as management balanced record results with a realistic view of looming headwinds. Executives highlighted strong commercial momentum, blockbuster status for Epidiolex, and game‑changing oncology data, while acknowledging slower 2026 growth, rising R&D spend, and competitive pressure in sleep that could test investor patience.
Record revenue and 21 years of topline growth
Jazz delivered record 2025 revenue of $4.3 billion, marking its 21st straight year of topline growth and underscoring the durability of its portfolio. Fourth quarter revenue hit an all‑time high of $1.2 billion, up 10% year over year and showing that momentum remained solid exiting the year despite mounting competition in key markets.
Strong cash generation and a fortified balance sheet
Non‑GAAP adjusted net income reached about $522 million in 2025, translating to adjusted EPS of $8.38 and confirming that Jazz remains solidly profitable. Cash from operations of roughly $1.4 billion and year‑end cash and investments of $2.4 billion give the company significant financial flexibility for pipeline investment, deals, and shareholder‑friendly capital allocation.
Xywav growth offsets early sleep market pressure
Xywav continued to anchor the sleep franchise with 2025 revenue of approximately $1.7 billion, up 12% year over year, including $465 million in the fourth quarter, up 16%. The drug now serves more than 16,000 patients, with around 500 net additions in the fourth quarter and over 2,000 in 2025, while idiopathic hypersomnia patients jumped about 34%, signaling continued share gains.
Epidiolex hits blockbuster scale with room to expand
Epidiolex officially entered blockbuster territory, generating $1.1 billion in 2025 revenue, up 9% year over year on 7% volume growth and $287 million in the fourth quarter. Management emphasized continued investment to boost adult uptake and advance new formulations, suggesting the asset still has meaningful runway despite maturing pediatric indications.
Zanidatamab showcases practice‑changing oncology data
Zanidatamab, to be marketed as Ziihera, delivered practice‑changing Phase III results in first‑line HER2‑positive metastatic gastroesophageal adenocarcinoma when combined with atezolizumab and chemotherapy. The regimen produced median overall survival of more than two years, over a seven‑month improvement versus control and a 28% reduction in the risk of death, plus more than four months of progression‑free survival benefit.
Regulatory momentum for zanidatamab and launch plans
The U.S. Food and Drug Administration granted Breakthrough Therapy designation for zanidatamab, providing an expedited regulatory path for this high‑impact asset. Jazz plans a supplemental biologics license application under real‑time oncology review in the first quarter and is targeting a potential U.S. launch in the second half of 2026, positioning oncology as a key future growth engine.
Modeyso launch shows promise but remains label‑limited
Following the April acquisition of Chimerix, Jazz launched Modeyso in August and generated $48 million of revenue in roughly four and a half months, with more than 360 patients treated in 2025. Management sees a U.S. commercial opportunity above $500 million, but stressed that realizing this depends heavily on broader uptake and positive results from the ACTION trial.
Zepzelca expansion supports oncology growth
Zepzelca’s performance highlighted the strength of Jazz’s rare oncology strategy, with 2025 revenue reaching $307 million and fourth quarter sales near $90 million, up 15% year over year. Expansion into first‑line maintenance in combination with atezolizumab is driving incremental demand and further embedding Zepzelca in treatment algorithms for small cell lung cancer.
Litigation resolutions and tax wins extend cash runway
Management noted that nearly all major litigation matters have been resolved, including Epidiolex ANDA cases, extending exclusivity runways into the very late 2030s and de‑risking long‑term revenue. Jazz also recognized a deferred tax asset tied to the Chimerix deal that is expected to cut future cash taxes by more than $200 million and booked proceeds from the sale of a priority review voucher.
Pipeline progress underpins long‑term growth story
Jazz continued to invest in its early pipeline, with 2025 milestones including in‑house candidate JZP047 entering Phase I for absence epilepsy and a Phase Ib study of Epidiolex in focal onset seizures. The company also highlighted a slate of registrational and exploratory trials across oncology and rare diseases, including breast cancer and tumor basket studies, aiming to diversify beyond sleep.
Generic pressure intensifies in the sleep franchise
Competition in sleep is heating up as two generic high‑sodium oxybate products launched and Hikma’s authorized generic remains active, pressuring legacy Xyrem. Jazz now expects Rare Sleep revenue to decline from $2.01 billion in 2025 to between $1.8 billion and $1.9 billion in 2026, with limited impact on branded Xywav early in 2026 but tougher dynamics anticipated in the second half.
Guidance signals slower growth and higher R&D
For 2026, Jazz guided total revenue to a range of $4.25 billion to $4.50 billion, implying roughly 2.5% growth at the midpoint and a marked slowdown from 2025’s pace as sleep headwinds bite. The company expects double‑digit gains from rare oncology and epilepsy products, but is also guiding to higher non‑GAAP R&D of $725 million to $775 million and slightly lower gross margins due to royalties and potential tariffs.
Program rationalization with JZP441 termination
The company ended development of JZP441, an orexin‑targeted sleep program partnered with Sumitomo, and terminated that collaboration, which removes one pipeline asset but frees resources for higher‑priority projects. Management framed the move as disciplined portfolio pruning in a crowded sleep market, where the focus will shift toward differentiated assets and oncology opportunities.
Modeyso’s upside hinges on ACTION trial results
While early Modeyso revenue is encouraging, management reiterated that the path to more than $500 million in U.S. sales depends on expanding its label beyond the current post‑progression use. The pivotal ACTION trial is designed to support frontline use immediately after radiotherapy rather than waiting for disease progression, which could dramatically enlarge the addressable market if successful.
Potential dilution from in‑the‑money convertibles
Jazz guided to fully diluted shares outstanding of 65 million to 66 million for 2026, reflecting issuance under employee compensation plans and the impact of in‑the‑money convertible notes maturing in 2026 and 2030. Investors will need to factor this potential dilution into valuation models, particularly in the absence of earnings per share guidance for the coming year.
Guidance points to stable but moderated 2026 outlook
Management’s 2026 outlook calls for low‑single‑digit topline growth as Rare Sleep revenue declines to $1.8 billion to $1.9 billion amid multiple generics and a modest step‑down in Hikma royalties. Growth is expected to be driven by Epidiolex, Modeyso, Ziihera, and Zepzelca, with non‑GAAP gross margins of 90% to 91%, SG&A of $1.26 billion to $1.32 billion, higher R&D, a tax rate of 11.5% to 13.5%, and 65 million to 66 million diluted shares.
Jazz’s earnings call painted a picture of a company in transition, shifting from reliance on its legacy sleep franchise to a more diversified mix anchored by epilepsy and oncology. While growth will slow in 2026 and investors must watch competition, spending, and dilution, record cash flow, strong late‑stage data, and extended IP runways suggest Jazz is building a more resilient long‑term story for shareholders.
